Is Selpercatinib on the market?

Selpercatinib is still under investigation in clinical trials NCT04211337, but it received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 8, 2020, for a specific RET-driven cancer indication to Loxo, a subsidiary of Eli Lilly and Company. Oncology has licensed Retevmo and it is currently marketed under the brand name Retsevmo. Serpatinib has also been approved by the European Commission.

Serpatinib is the first therapy approved specifically for patients with cancer and RET gene alterations. It is designed to treat cancers that display rearrangements during transfection of (RET) gene alterations, including RET fusion-positive non-small cell lung cancer (NSCLC), RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer (MTC). Continued approval may depend on future confirmatory trials.

The original drug Serpatinib has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. Serpatinib marketed overseas The original drug has a US version and a European version. The price of the US version is about 150,000 yuan per box of 80mg*60 pills. The price of the European version of 80mg*56 pills per box is about 21,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also serpatinibgeneric drugs produced abroad. The specification produced by a Bangladesh pharmaceutical factory is 40mg*30 pills per box and the price is about 4,300 yuan (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug.